Wells Fargo & Company Protara Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TARA
# of Institutions
43Shares Held
10.4MCall Options Held
25KPut Options Held
12.7K-
Opaleye Management Inc. Boston, MA2.3MShares$4.29 Million1.23% of portfolio
-
Ra Capital Management, L.P. Boston, MA1.9MShares$3.53 Million0.06% of portfolio
-
Stem Point Capital LP New York, NY984KShares$1.83 Million0.6% of portfolio
-
Boxer Capital, LLC San Diego, CA812KShares$1.51 Million0.09% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il665KShares$1.24 Million0.0% of portfolio
About Protara Therapeutics, Inc.
- Ticker TARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,267,400
- Market Cap $21M
- Description
- Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...